Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
In addition to the data provided
2025-01-09

In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr
-
Introduction Lysophosphatidic acid LPA is
2025-01-09

Introduction Lysophosphatidic Canagliflozin (LPA) is a key, serum-borne phospholipid, regulating a number of cellular processes such as proliferation, migration and differentiation through its interaction with G-protein coupled receptors. LPA receptor signaling has been implicated in several disea
-
br Materials and methods br Results br Discussion In
2025-01-09

Materials and methods Results Discussion In this study, the orphan receptor GPR25 was cloned from several representative vertebrate species including zebrafish. Although the overall amino S1P agonist Fingolimod sequence identity among these species is not high (38–52%), our synteny analysi
-
br Conclusions and perspectives In
2025-01-09

Conclusions and perspectives In view of the evidences supporting that ψUTP-modified mRNA MAS receptors mediate the effects of AT1 antagonists (Iwai et al., 2012, Ohshima et al., 2014, Pernomian et al., 2015, Schuchard et al., 2015), the prime targets from the perspectives on future directions in
-
First the complete canonical brain original
2025-01-09

First, the complete canonical brain original RAS (Angiotensinogen, Renin, Angiotensin I, Angiotensin Converting Enzyme (ACE), Angiotensin II) has not been conclusively identified in any specific cell type within the brain [1]. Validated evidence for the presence of brain Angiotensinogen and ACE was
-
AMP activated protein kinase AMPK is composed of and
2025-01-09

AMP-activated protein kinase (AMPK) is composed of α-, β-, and γ-subunits [17,18]. Phosphorylation of α-subunit at Thr-172 residue is essential for AMPK activation [17,18]. The serine/threonine kinase coordinates metabolic pathways in response to energy supply and demand [17,18]. Studies have shown
-
The number of times an
2025-01-09

The number of times an animal reared was the only emotional behavior that was significantly higher in the young mice than in the middle-aged group. This may be explained by diminished curiosity or augmented ambulation with aging (Lalonde and Strazielle, 2008). A recent study showed that middle-aged
-
Inflammatory factors released by activated cells during AD
2025-01-09

Inflammatory factors released by activated cells during AD are very important for the disease progression. Not only several inflammatory cytokines, such as IL-1β, IL-18, and IL-33, but also anti-inflammatory ones, as IL-10 and IL-13, are upregulated in the brain of AD patients (Morimoto et al., 2011
-
Our results add to previously published
2025-01-09

Our results add to previously published data on the contribution of ALDH3A1 to the optical properties of the cornea. Specifically, the study by Nees et al. (2002) was among the first to examine whether ALDH3A1 serves as a structural component in the cornea and similarly to lens crystallins. Their ex
-
Introduction Diabetic nephropathy is a rapidly growing cause
2025-01-08

Introduction Diabetic nephropathy is a rapidly growing cause of end-stage renal disease [1]. Glomerular, tubular and vascular toxicity resulting from hyperglycemia (glucotoxicity) have been evaluated extensively at the molecular level as contributing factors for diabetic nephropathy [[1], [2], [3]]
-
A borderline significant effect of women s age has been
2025-01-08

A borderline significant effect of women's age has been observed for ADA6 only. For ADA2 the proportion of the *1/*1 genotype is 69.4% in women aged ≤36 years vs. 66.9% in women aged ≥36 years (p=0.944). The proportion of ADA6*1 allele carriers is 32.6% in women aged ≤36 years vs. 49. 8 in women age
-
Ac-DEVD-pNA for cell lysates In conclusion AXL overexpressio
2025-01-08

In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
-
Compounds are representatives of an array of MBG targets
2025-01-08

Compounds – are representatives of an array of MBG targets (, ) related to imidazole standard that were synthesized and initially tested in a rat CYP17 lyase screening assay (). The inhibitors were synthesized as racemates by coupling of 6,7-dimethoxy-naphthalene-2-isopropyl ketone with the requisi
-
br The role of cytochrome b with cytochrome P
2025-01-08

The role of cytochrome b5 with cytochrome P450 17α-hydroxylase/17,20-lyase Conclusion Acknowledgments LLM and RJR wish to thank the Australian Research Council and the National Health and Medical Research Council of Australia for funding. The problem One area of modern medicine that con
-
For the NSCLC patients with EGFR activating mutations
2025-01-08

For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment
16734 records 32/1116 page Previous Next First page 上5页 3132333435 下5页 Last page